Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Protagonist Therapeutics Inc (PTGX)

Protagonist Therapeutics Inc (PTGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,013,782
  • Shares Outstanding, K 62,516
  • Annual Sales, $ 434,430 K
  • Annual Income, $ 275,190 K
  • EBIT $ 19 M
  • EBITDA $ 13 M
  • 60-Month Beta 2.26
  • Price/Sales 24.60
  • Price/Cash Flow 18.23
  • Price/Book 7.98

Options Overview Details

View History
  • Implied Volatility 49.34% (-1.70%)
  • Historical Volatility 32.35%
  • IV Percentile 42%
  • IV Rank 13.40%
  • IV High 138.06% on 02/21/25
  • IV Low 35.62% on 11/17/25
  • Expected Move (DTE 7) 5.38 (6.71%)
  • Put/Call Vol Ratio 0.17
  • Today's Volume 873
  • Volume Avg (30-Day) 286
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 15,696
  • Open Int (30-Day) 15,047
  • Expected Range 74.84 to 85.60

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.53
  • Number of Estimates 5
  • High Estimate -0.16
  • Low Estimate -0.73
  • Prior Year 1.98
  • Growth Rate Est. (year over year) -126.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
79.18 +1.31%
on 01/07/26
96.54 -16.90%
on 12/15/25
-8.34 (-9.42%)
since 12/09/25
3-Month
65.75 +22.01%
on 10/10/25
96.54 -16.90%
on 12/15/25
+13.18 (+19.66%)
since 10/09/25
52-Week
33.70 +138.04%
on 02/25/25
96.54 -16.90%
on 12/15/25
+42.60 (+113.24%)
since 01/08/25

Most Recent Stories

More News
Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026

NEWARK, CA / ACCESS Newswire / January 7, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will...

PTGX : 80.22 (+0.02%)
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)

Rusfertide Is a First-in-Class Investigational Hepcidin Mimetic That Targets Red Blood Cell Overproduction (Erythrocytosis) in Polycythemia Vera ...

PTGX : 80.22 (+0.02%)
TAK : 16.31 (-0.37%)
Breakthrough ASH Data Drives Blood Cancer Market To $240B Valuation

Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – The 2025 American Society of Hematology meeting showcased pivotal advances in blood cancer treatment, with...

PTGX : 80.22 (+0.02%)
KPTI : 8.68 (+6.24%)
GTBP : 0.6770 (-0.44%)
GSK : 50.39 (+0.34%)
TAK : 16.31 (-0.37%)
Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice

NEW YORK, NY / ACCESS Newswire / November 27, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") today announced that it has received a notification letter from the Nasdaq Listing Qualifications...

PTGX : 80.22 (+0.02%)
PTIX : 0.6221 (-5.50%)
Protagonist Therapeutics: Q3 Earnings Snapshot

Protagonist Therapeutics: Q3 Earnings Snapshot

PTGX : 80.22 (+0.02%)
Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Following the NDA submission for icotrokinra treatment of adults and adolescents with moderate to severe plaque psoriasis to the U.S. FDA in July, the European Medicines Agency (EMA) application was submitted...

PTGX : 80.22 (+0.02%)
Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting

NEWARK, CALIFORNIA / ACCESS Newswire / November 3, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that clinical data on rusfertide in polycythemia vera, including the...

PTGX : 80.22 (+0.02%)
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences

Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing endoscopic...

PTGX : 80.22 (+0.02%)
Johnson & Johnson's M&A Strategy Is the Real Story for Investors

Johnson & Johnson’s rumored Protagonist buyout demonstrates its proven M&A strategy: divesting low-growth units to fund high-margin, innovative assets.

PTGX : 80.22 (+0.02%)
JNJ : 204.39 (-0.66%)
KVUE : 16.83 (-0.94%)
Protagonist Therapeutics (PTGX) Gets a Buy from BMO Capital

In a report released today, Evan Seigerman from BMO Capital maintained a Buy rating on Protagonist Therapeutics, with a price target of $112.00. The company’s shares closed last Friday at $87.00.Elevate...

PTGX : 80.22 (+0.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and...

See More

Key Turning Points

3rd Resistance Point 83.31
2nd Resistance Point 82.35
1st Resistance Point 81.29
Last Price 80.22
1st Support Level 79.27
2nd Support Level 78.31
3rd Support Level 77.25

See More

52-Week High 96.54
Last Price 80.22
Fibonacci 61.8% 72.54
Fibonacci 50% 65.12
Fibonacci 38.2% 57.70
52-Week Low 33.70

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar